About Malonyl-CoA-acyl carrier protein transacylase, mitochondrial
Malonyl-CoA-acyl carrier protein transacylase, mitochondrial (MCAT) is a protein
from Homo sapiens identified by UniProt accession
Q8IVS2, 390 residues long.
MolForge cross-references it against 0 known binders and
393 disease associations.
Target properties
| Protein name | Malonyl-CoA-acyl carrier protein transacylase, mitochondrial |
| UniProt accession | Q8IVS2 |
| Gene | MCAT |
| Organism | Homo sapiens |
| Length | 390 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (393)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- Autosomal recessive isolated optic atrophy · score 0.37
- mitochondrial DNA measurement · score 0.27
- hereditary optic neuropathy · score 0.18
- prostate carcinoma · score 0.09
- mean corpuscular hemoglobin · score 0.06
- neoplasm · score 0.06
- platelet count · score 0.05
- Huntington disease · score 0.04
- cardiomyopathy · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IVS2-F1 | alphafold | PREDICTED | 87.05 | — |
Amino-acid sequence (390 residues)
MSVRVARVAW VRGLGASYRR GASSFPVPPP GAQGVAELLR DATGAEEEAP WAATERRMPG QCSVLLFPGQ GSQVVGMGRG LLNYPRVREL YAAARRVLGY DLLELSLHGP QETLDRTVHC QPAIFVASLA AVEKLHHLQP SVIENCVAAA GFSVGEFAAL VFAGAMEFAE GLYAVKIRAE AMQEASEAVP SGMLSVLGQP QSKFNFACLE AREHCKSLGI ENPVCEVSNY LFPDCRVISG HQEALRFLQK NSSKFHFRRT RMLPVSGAFH TRLMEPAVEP LTQALKAVDI KKPLVSVYSN VHAHRYRHPG HIHKLLAQQL VSPVKWEQTM HAIYERKKGR GFPQTFEVGP GRQLGAILKS CNMQAWKSYS AVDVLQTLEH VDLDPQEPPR
Explore Malonyl-CoA-acyl carrier protein transacylase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets